Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal prognosis for the patient. This is due to limited diagnostic options for the early detection of the disease as well as its rather aggressive nature. Despite major advances in oncologic research in general, the treatment options in the clinic for PDAC have only undergone minor changes in the last decades. One major treatment advance would be the successful targeting of the oncogenic driver KRAS^mut. In the past, the indirect targeting of KRAS has been exploited, e. g., via upstream inhibition of receptor tyrosine kinases or via downstream MEK or PI3K inhibition. However, the experience gained from clinical trials and from the clinic itself in the treatment of KRAS^mut cancer ent

SUBMITTER: Nollmann FI 

PROVIDER: S-EPMC7459579 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature